Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study
Liver Cancer · 09.12.2025 · 1-11
DOI: 10.1159/000549979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 09.12.2025. Verfasst von Ko Hashimoto und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
This study aimed to evaluate the effect of sandwiching on-demand transcatheter arterial chemoembolization (TACE) during atezolizumab (Atezo) and bevacizumab (Bev) therapy on overall survival (OS) and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC).
Methods
We retrospectively analyzed 398 patients who started Atezo/Bev therapy between October 2020 and April 2024. Overall, 245 patients were included: 51 in the ABC-TACE sandwich group and 194 in the Atezo/Bev alone group. Propensity score matching was performed to balance baseline characteristics, resulting in 49 matched patients per group. OS and PFS were analyzed using the Kaplan-Meier methods, with landmark analysis to adjust for immortal time bias. Multivariate analysis identified independent predictors of OS and PFS.
Results
The ABC-TACE sandwich group had significantly longer OS (median, not reached vs. 21.0 months, p < 0.05) and PFS (18.7 months vs. 11.2 months, p < 0.05) than the Atezo/Bev alone group. Landmark analysis showed prolonged OS at multiple time points in the ABC-TACE sandwich group (p < 0.05, p < 0.05, p = 0.078). TACE independently contributed to both OS and PFS. No significant differences in adverse events were observed between the groups. No deterioration in the Child-Pugh score was observed before and after TACE (p = 0.976).
Conclusion
Sandwiching TACE during Atezo/Bev therapy may improve survival outcomes for unresectable HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Clinical and Molecular Genetics, Genomic Medicine Center, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Gastroenterology, Hiroshima Memorial Hospital, Hiroshima, Japan.
- Department of Gastroenterology, NHO Higashihiroshima Medical Center, Hiroshima, Japan.
- Department of Gastroenterology, JA Hiroshima General Hospital, Hiroshima, Japan.
Zitieren
APA
Hashimoto, K., Kawaoka, T., Emori, T., Tanaka, A., Shirane, Y., Miura, R., Fujii, Y., Nakahara, H., Yamaoka, K., Uchikawa, S., Fujino, H., Ono, A., Murakami, E., Miki, D., Hayes, C. N., Hiramatsu, A., Amioka, K., Nonaka, M., Aisaka, Y., …, & Oka, S. (2025). Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study. Liver Cancer, 1-11. https://doi.org/10.1159/000549979
Vancouver
Hashimoto K, Kawaoka T, Emori T, Tanaka A, Shirane Y, Miura R, et al. Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study. Liver Cancer. 2025:1-11. doi:10.1159/000549979
BibTeX
@article{Hashimoto2025,
author = {Hashimoto, Ko and Kawaoka, Tomokazu and Emori, Tomoaki and Tanaka, Aiko and Shirane, Yuki and Miura, Ryoichi and Fujii, Yasutoshi and Nakahara, Hikaru and Yamaoka, Kenji and Uchikawa, Shinsuke and Fujino, Hatsue and Ono, Atsushi and Murakami, Eisuke and Miki, Daiki and Hayes, C Nelson and Hiramatsu, Akira and Amioka, Kei and Nonaka, Michihiro and Aisaka, Yasuyuki and Morio, Kei and Moriya, Takashi and Teraoka, Yuji and Kono, Hirotaka and Suehiro, Yosuke and Masaki, Keiichi and Ohya, Kazuki and Takaki, Shintaro and Mori, Nami and Tsuji, Keiji and Kosaka, Yumi and Nakahara, Takashi and Aikata, Hiroshi and Tsuge, Masataka and Oka, Shiro},
title = {Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study},
journal = {Liver Cancer},
year = {2025},
pages = {1--11},
doi = {10.1159/000549979}
}
EUVIMED